Search results
Results From The WOW.Com Content Network
Lorcaserin, marketed under the brand name Belviq, [4] [5] was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating serotonin receptor the 5-HT 2C receptor in the hypothalamus , a region of the brain which is known to control appetite. [ 6 ]
Lorcaserin (Belviq) was FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer. [ 11 ] Cannabinoid receptor antagonists were developed to treat obesity because researchers noticed that cannabinoid agonists (such as THC , the main pharmacologically active component ...
Lorcaserin (Belviq) 2020 US Increased risk of cancer. [32] Lumiracoxib (Prexige) 2007–2008 Worldwide Liver damage Lysergic acid diethylamide (LSD) 1950s–1960s Marketed as a psychiatric drug; withdrawn after it became widely used recreationally. Now illegal in most of the world. Mebanazine: 1975 UK Hepatotoxicity, drug intereaction. [3 ...
Pholcodine can trigger allergic reactions and is common in cough syrups
Lorcaserin is the only agent that has completed phase III clinical trials, and achieved US Food and Drug Administration (FDA) approval. However it was later withdrawn from the market in February 2020 due to a higher risk of malignancy in a randomized trial of lorcaserin. [39] Previously approved agents were subsequently removed from the US ...
Lorcaserin (withdrawn in the United States by the FDA due to an increased risk of cancer) [16] Mazindol; Mefenorex; Phentermine; Sibutramine † (in some countries withdrawn from the market because of concerns regarding its cardiovascular effects) Topiramate
Lorcaserin used to be approved by the Food and Drug Administration for use in the treatment of obesity before being withdrawn due to cancer risk. [72] Recombinant human leptin is very effective in those with obesity due to congenital complete leptin deficiency via decreasing energy intake and possibly increases energy expenditure. This ...
Sibutramine, formerly sold under the brand name Meridia among others, is an appetite suppressant which has been discontinued in many countries. It works as a serotonin–norepinephrine reuptake inhibitor (SNRI) similar to certain antidepressants.